These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 24382582)

  • 1. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.
    Gangi A; Mirocha J; Leong T; Giuliano AE
    Ann Surg Oncol; 2014 Dec; 21(13):4098-103. PubMed ID: 25155393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of correlation between breast cancer molecular subtypes and prognosis of patients receiving breast-conserving therapy].
    Geng WW; Zhang B; Li DH; Liang XR; Cao XC
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(20):1571-3. PubMed ID: 24028726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
    Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
    Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis.
    Wang J; Xie X; Wang X; Tang J; Pan Q; Zhang Y; Di M
    Surg Oncol; 2013 Dec; 22(4):247-55. PubMed ID: 24144808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy.
    Braunstein LZ; Taghian AG; Niemierko A; Salama L; Capuco A; Bellon JR; Wong JS; Punglia RS; MacDonald SM; Harris JR
    Breast Cancer Res Treat; 2017 Jan; 161(1):173-179. PubMed ID: 27807809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
    Steward L; Conant L; Gao F; Margenthaler JA
    Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
    Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
    Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
    Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
    Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
    Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.